Glioma
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Glioma
- Therapeutic area
- Neurology
- glioma
- glial neoplasm
- glial tumor
- glial tumour
- glioma
- neoplasm of neuroglia
- neoplasm of the neuroglia
- neuroglial neoplasm
- neuroglial tumor
- neuroglial tumour
- tumor of neuroglia
- tumor of the neuroglia
- tumour of neuroglia
- tumour of the neuroglia
- Severity
- Mild
- Neurology
- Oncology
- MONDO ID
- MONDO:0021042
- Parent condition
- MONDO:0021193
Related records
Broader conditions (10)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Nervous system disorder
- Nervous system neoplasm
- Neuroepithelial neoplasm
Narrower conditions (204)
- 22q-related schwannomatosis
- Acoustic neuroma
- Adult anaplastic ependymoma
- Adult astrocytic tumor
- Adult brain ependymoma
- Adult brainstem astrocytoma
- Adult brainstem glioma
- Adult brainstem gliosarcoma
- Adult brainstem mixed glioma
- Adult glioblastoma
- Adult infiltrating astrocytic neoplasm
- Adult malignant schwannoma
- Adult oligodendroglioma
- Adult spinal cord ependymoma
- Adult spinal cord glioblastoma
- Anaplastic astrocytoma
- Anaplastic ependymoma
- Anaplastic oligoastrocytoma
- Anaplastic oligodendroglioma
- Anaplastic pleomorphic xanthoastrocytoma
Trials (1,439)
- (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
- [11C]Acetate PET in Patients With Glioma
- [18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
- [18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy
- [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
- 11C-Methionine PET as Prognostic Marker of Gliomas
- 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
- 131-I-TM-601 Study in Adults With Solid Tumors
- 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
- 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
- 18F-DOPA-PET in Planning Surgery in Patients With Gliomas
- 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
- 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
- 18F-FET PET/CT in the Management of Glioma
- 18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas
- 18F-Floretyrosine Expanded Access Program
- 18F-Fluciclovine PET-MRI in High-grade Glioma
- 18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
- 3D Ultra Sound for Resection of Brain Tumors
Approved drugs (6)
- Aminolevulinic acid hydrochloride
- Carmustine
- Dabrafenib mesylate
- Iopamidol
- Temozolomide
- Trametinib dimethyl sulfoxide
Drugs in development (17)
- Afatinib Phase 2
- Afatinib dimaleate Phase 2
- Bevacizumab Phase 2
- Fasedienol Phase 2
- Irinotecan Phase 2
- Isotretinoin Phase 3
- KRN-633 Phase 1
- NM-404 I-124 Phase 2
- Obrixtamig Phase 1
- Paclitaxel Phase 2
- Pelareorep Phase 1
- PF-06840003 Phase 1
- Pritumumab Phase 2
- Ripretinib Phase 1
- Tenatumomab Phase 3
- Ubidecarenone Phase 2
- Vebreltinib Phase 1
Other linked drugs (14)
- Alanine
- BMX-001
- Dextrose
- Dordaviprone
- DS-1001B
- Galunisertib
- Midazolam
- Olutasidenib
- Omburtamab
- Phenylalanine
- Procarbazine hydrochloride
- Tozuleristide
- Vorasidenib
- WP-1122